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Abstract— The release of the anti-cancer drug paclitaxel (PTX) 
from microspheres of both a bioresorbable poly(ε-caprolactone-
oxyethylene-ε-caprolactone) tri-block copolymer and of 
polyurethanes containing either copolymers with the same 
composition and different molecular weights or poly(ε-caprolactone) 
diol as soft segments was studied. The microspheres, both loaded and 
not with PTX, were prepared by emulsion-evaporation technique, 
then characterized by SEM and DSC. The quantities of PTX released 
were measured by HPLC. The results showed slow and very regular 
releases, which fit very well the Peppas equation, Mt/M∞ = k · tn, 
where Mt is the amount of solute released at the time t, M∞ is the 
amount of drug released at the plateau condition, k represents the 
Peppas kinetic constant and n the diffusion order. Most n values are 
consistent with non-Fickian release mechanisms, with the exceptions 
of two less hydrophilic polyurethanes. 
 
Keywords—Controlled release, microspheres, paclitaxel, 
poly(ester-ether-ester)s, polyurethanes.  
I. INTRODUCTION 
HE poly(ester-ether-ester) tri-block copolymers have been 
proposed as bioresorbable materials since many years [1], 
[2]; biodegradable polyurethanes containing either them or 
polyester diols as soft segments were synthesized and tested 
more recently [3]-[6]. The development of the non-catalyzed 
synthesis of the tri-block copolymers [7]-[9] allowed to avoid 
the use, as a catalyst, of 2-ethylhexanoic acid, tin(II) salt, 
commonly known as stannous octoate, which was found to be 
cytotoxic [10]. The copolymers having poly(ε-caprolactone) 
chains as the polyester blocks (PCL-POE-PCL) were tested 
for cell adhesion and proliferation and cytotoxicity [11], as 
well as for cytocompatibility and hemocompatibility [12]. All 
the copolymers were found to be biocompatible with respect 
to the tests carried out. The degradation in vitro of the 
copolymers both in the absence and in the presence of cells 
was also tested [13], and the degradation product, 6-
hydroxyhexanoic acid, were found to not alter the endothelial 
metabolism [14], and to modulate the endothelin release by 
human umbilical vein endothelial cells, with no significant 
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alteration of the vasoconstrictor-vasodilator balance [15]. 
Polyurethanes were found to be enzymatically degradable by 
chymotrypsin [6]. PCL-POE-PCL was melt-spun to make 
fibers to be used as bioresorbable suture threads [16]. 
Composites of hydroxyapatite and copolymers with the same 
monomer composition were prepared both by direct 
copolymer synthesis [17] and by blending; the latter material 
was employed to make periodontal membranes, which were 
successfully tested for the bioresorption in vitro and in vivo 
[18]. A parallel ε-caprolactone homopolymerization, initiated 
by hydroxyapatite [17], [19], glasses [20] and alumina [21], 
was also found. In the last system, however, the presence in 
the product of bioresorbable polyester chains bonded to the 
Al3+ ions, which are toxic especially for neuronal cells [22], 
makes uncertain the complete biocompatibility of the 
composite. The release of the anti-cancer drug 5-fluorouracil 
by thin sheets of PCL-POE-PCL was also investigated [23]; 
the dependence of the release kinetics on the interactions 
between the copolymers and the drug was evaluated with ab 
initio calculations at the Hartree-Fock and second order 
Møller-Plesser levels [24]. In recent years, new therapies for 
tumors are being proposed, like anti-angiogenic treatments 
[25] and recombinant manganese superoxide dismutase [26]. 
This paper regards the release of a “classical” anti-cancer 
drug, the 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-
11-en-9-one-4,10-diacetate-2-benzoate 13-ester with (2R,3S)-
N-benzoyl-3-phenylisoserine (paclitaxel, PTX). PTX (see 
Fig.1) is a diterpenoid first isolated from the bark of the 
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 Fig. 1 structural formula of paclitaxel 
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western yew Taxus brevifolia. It aids the polymerization of 
tubulin dimers to form microtubules, which are not only very 
stable, but also dysfunctional, leading to cell death; this 
property makes PTX a very effective anti-tumor agent [27]. 
The use of PTX in cancer therapy gives rise to the problem of 
its administration to the patients. Direct intravenous 
administration was found to have undesirable side effects on 
healthy cells [27]-[30], so that different PTX administration 
techniques were needed. Films of chitosan-poly(vinyl alcohol) 
blends made by casting, both as such and cross-linked with 
pentane-1,5-dial (glutaraldehyde), released a very scarce 
percentage of the PTX initially put into them [31]. A more 
efficacious drug delivery technique is the use of nanoparticles 
[32] or microspheres [33]. Since the release of PTX from 
microspheres of biodegradable macromolecular materials was 
tested successfully [33]-[40], an attempt has been made to 
study the controlled release of PTX from microspheres of both 
a PCL-POE-PCL and of polyurethanes containing either PCL-
POE-PCLs with different molecular weights or a poly(ε-




The PCL-POE-PCL copolymer used as such was the 
previously synthesized C27 sample [12], having an ester (CL) 
to ether (OE) units 66:34 molar ratio, a central polyether chain 
(POE) with a mean number molecular weight (Mn) value of 
3.5 × 104, and a total mean Mn value of 20.37 × 104. The 
polyurethanes were synthesized using the technique described 
in a previous paper [6], with: PCL-POE-PCL (CL:OE = 65:35, 
POE Mn = 600, total Mn = 3300), 2,6-diisocyanatohexanoic 
acid ethyl ester (LDI), and 1,4-cyclohexane dimethanol 
(CDM, Aldrich) as the chain extender (PUC35, total Mn = 1.94 
× 104); PCL-POE-PCL (CL:OE = 50:50, POE Mn = 600, total 
Mn = 2200), 2,6-diisocyanatohexanoic acid ethyl ester (LDI), 
and 1,4-cyclohexane dimethanol (CDM, Aldrich) as the chain 
extender (PUC50, total Mn = 1.67 × 104); PCLdiol (Aldrich, 
mean Mn = 2000), LDI, and CDM (PUH, total Mn = 4.23 × 
104); PCLdiol (mean Mn = 2000), LDI, and L-lysine ethyl ester 
as the chain extender (PUL, total Mn = 9.22 × 104). PTX 
(Sorin, Italy) was used as supplied.  
B. Microsphere fabrication 
The microspheres of both the PCL-POE-PCL and the 
polyurethanes, loaded with PTX, were prepared adding to 5 
mL of each macromolecule solution 60 g/L in CH2Cl2 either 
15 or 60 mg of PTX, in order to obtain drug/polymer 
percentages of 5% and 20% w/w, respectively. Each solution 
was rapidly poured into 100 mL of 25 g/L aqueous solution of 
poly(vinyl alcohol) (PVA, Aldrich) as an emulsifier in a three-
neck flask, and the two-phases liquid was stirred at 800 rpm 
for 2 h; 1,5 mL (1,62 g) of Tween 80 (TW, Acros) were 
added, as an additional emulsifier, to one of the solutions 
containing PUC50, then the so obtained micro-emulsions were 
stirred at 250 rpm overnight, keeping the flask opened to allow 
CH2Cl2 evaporation. The microspheres were separated by 
centrifugation, washed tenfold with H2O and lyophilized. The 
percentage encapsulation efficiency (%EE) was calculated 
according to Freiberg and Zhu [41]. The mean values of %EE 
of the materials used to fabricate the microspheres are listed in 
Table I. “Placebo microspheres” without PTX were also 
prepared by the same procedure. 
C. Characterization of the microspheres 
Scanning Electron Microscopy (SEM) was carried out, 
using a JEOL T-300 instrument, on samples coated with 24 
carat gold in a vacuum chamber. Differential scanning 
calorimetry (DSC) was carried out in triplicate with a Perkin 
Elmer DSC7 apparatus, on 5 to 7 mg of both PTX loaded and 
placebo microspheres in Al pans, from 40.00 to 240.00°C at 
20.00°C per min under N2 flux. 
D. Paclitaxel release 
Microspheres in the delivery solution 
10 mg of PTX-loaded microspheres, loaded with both 5% 
and 20% in weight of drug, were weighted and immersed in 5 
ml of the delivery medium composed of a phosphate buffered 
solution (PBS) at pH 7.4 containing 0.05% (w/v) in sodium 
dodecyl sulphate (SDS, Sigma). In order to avoid the tendency 
of the microspheres to aggregate, samples were sonicated after 
the immersion in the delivery medium. The use of the SDS 
surfactant was finalized to increase the solubility of the PTX 
in water and also to reproduce a condition more similar to the 
in vivo one. Samples were maintained in a lightly stirred bath 
at a fixed temperature (37°C ± 1°C) through all the testing 
period (34 days). Withdraws from the delivery medium were 
carried out at established times and the delivery solution was 
replaced by fresh solution after each withdraw, in order to 
maintain a sink condition. The sink condition occurs when the 
amount of solute delivered is lower than 10-20% or even 30% 
of the maximum solubility of the solute in the dissolution 
medium [42]. For this reason, the solubility limit of PTX in 
Table I Percentage PTX encapsulation efficiencies (%EE) of 
the different microspheres used for the release 
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the delivery solution at 37°C has to be known. This value was 
gathered from literature [43] and used to verify if the sink 
condition was always verified. 
Released paclitaxel determination by HPLC 
Withdraws from the delivery medium were analyzed using 
high performance liquid chromatography (HPLC) at room 
temperature. The quantities of released PTX were calculated 
by means of a previously made calibration curve. HPLC was 
carried out using the following apparatus: a Perkin Elmer 410 
LC Pump, an Alltech C8 5U Alltima column having 4.6 mm 
diameter and 10 cm length, and a Perkin Elmer LC 90 UV 
Spectrophotometric Detector. The moving phase was a 58:42 
v/v CH3CN-H2O solution; the flux speed was 1 mL/min; the 
injected volume was 100 µL; the detector wavelength was 
kept at 230 nm; the PTX retention time was 3.04 min. 
Release kinetics evaluation 
The solute delivery kinetics was studied using two different 
mathematical models, expressed by the equations of Peppas 






Mt represents the amount of solute released at the generic 
time t, M∞ is the amount of drug released when the system 
reaches the plateau condition, k and n represent the Peppas 
kinetic constant and the diffusion order respectively, k0 is the 
Hopfenberg kinetic constant, c0 is the uniform starting drug 
concentration, a is the mean radius of the microspheres, m is a 
“shape factor” and was assumed to be 3 because of the 
spherical geometry of the delivery platform [44]. In the 
present work, the value of M∞ was considered equal to M0, 
considering that polymer used to obtain microspheres is 
biodegradable and it ensures that the entire amount of drug 
contained in the delivery platform is released at infinite times. 
Values of M0 were calculated considering the %EE values in 
Table I, using which the actual amounts of drug loaded within 
samples were estimated. Equations (1) and (2) are valid only 
for the first 60% of the total drug released [45]. Release orders 
allowed establishing the regime governing the release process. 
In particular, for spherical swellable samples, three different 
controlled release mechanisms can be identified [46]: n = 0.43 
(Fickian diffusion, concentration gradient-controlled regime), 
0.43 < n < 0.85 (anomalous non-Fickian transport) and n = 
0.85 (case-II transport, swelling-controlled regime). A not 
very different behavior can be supposed for the rather 
hydrophilic C27 copolymer. The hydrophilicity order of the 
other macromolecules, all less hydrophilic than C27, is the 
following: PUC50 > PUC35 > PUL > PUH. 
 
III. RESULTS AND DISCUSSION 
The SEM images of the microspheres, loaded with 5% 
PTX, are shown in Fig. 2 and Fig. 3. The regular spherical 
shape of the particles and their non-porous surface were 
confirmed by the SEM image of a single PUC50 microsphere, 
shown in Fig. 2. The microspheres made with C27 (Fig. 3a) 
appear very regular, with diameters ranging between 1.2 µm 
and 3.5 µm, whereas the PUC35 ones (Fig. 3b) show a less 
uniform diameter distribution. The distribution is more 
uniform for the microspheres of PUC50 made with only PVA 
as an emulsifier (Fig. 3c), and even more for those made with 
both PVA and TW (Fig. 3d). On the contrary, the 
microspheres made with the polyurethanes having PCL as a 
soft segment show the least uniform diameter distributions, 
although that of PUL (Fig. 3e) is more similar to that of 
PUC35 than that of PUH (Fig. 3f); however, some PUL 
particles have diameters more than double than the greatest 
ones of PUC35. Such characteristics can be related to the 
different structures of the macromolecular compounds. The 
presence of PEG in the macromolecules influences also the 
microsphere dimensions; indeed, those made with C27, 
PUC35, and PUC50 (Fig. 3 a-c) have mean dimensions 
smaller than those containing PCL (Fig. 3 e-f). As it is well 
known, the stability of a droplet of an organic solution 
dispersed in water phase depends on its total surface and on 
the interfacial tension, due to the different values of the 
electric field within the droplet and in the surrounding aqueous 
phase. The stability is inversely proportional to the surface 
energy, Es, equal to the product between the specific 
interfacial tension, γ, and the total surface, increasing when 
the diameter of each droplet decreases. Since the system tends 
to the minimum energy state, smaller microspheres are 
obtained with the macromolecules having better interactions 
with the aqueous phase, and then lower γ values. That also a 
more effective emulsifier decreases the γ value can be seen 





Fig. 2 SEM image of a single PUC50 microsphere; dimension bar = 0.5 
µm 
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The thermal properties, calculated from the DSC curves, of 
the materials in the form of microspheres, both loaded and not 
loaded with 20% PTX, are reported in Table II. The presence 
of the drug diminishes both the enthalpy foffrence (∆H) and 
the melting temperature (Tm), indicating a lower degree of 
cristallinity of the macromolecules. The greatest lowering 
occurs for the microspheres of C27 and PUC50 made with 
only PVA as an emulsifier; conversely, polyurethanes 
containing less or no OE unit, as well as PUC50 made with 
TW as an additional emulsifier, show little lowering of ∆H 
and Tm values. These values are in agreement with those of 
%EE reported in Table I; indeed, the strongest interactions 
occur between the polyether segments present in the polymer 
and the PTX, whose –NH and –OH groups can form hydrogen 
bonds with the “naked” electron pairs of the ether oxygen 
atoms, enhancing both the drug encapsulation and the 
perturbation of the macromolecular structure. Since the 
PUC50 microspheres made with both emulsifiers show a very 
low %EE value, the few PTX molecules present can cause 
only weak perturbations. As regarding the drug, Fig. 4 shows 
that the pure PTX melting endotherm at 223°C in curve (a) is 
totally absent in curve (b) of the loaded microsphere, as for the 
amorphous PTX [47]; the splitting of the C27 melting signal, 
with respect to that of the placebo particle in curve (c), 
indicates the presence of two phases, less and more ordered, of 
the copolymer. The behaviors of the other macromolecules are 
those summarized in Table II. 
 
 
Fig. 3 SEM images of microspheres of C27 (a), dimension bar = 5 µm; PUC35 (b), dimension bar = 10 µm; PUC50 only PVA (c), dimension bar = 10 µm; 
PUC50 PVA + TW (d), dimension bar = 10 µm; PUL (e), dimension bar = 20 µm; PUH (f), dimension bar = 100 µm. 
Table II Thermal properties of the microspheres, calculated 




Fig. 4 DSC traces of pure PTX (a) and of the microspheres, loaded (b) and 
not loaded (c) with 20% PTX 
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In Fig. 5 the values of Mt/M∞ versus time are reported for 
C27. Other materials also show a good fitting with the Peppas 
calculated curve, as can be seen from the correlation values 
reported in Table III. From literature, solubility limit of PTX 
in the PBS solution containing SDS was found to be 
0.08±0.01 mg/ml at 37°C [43]. Then, the perfect sink 
condition is satisfied if the concentration of PTX detected in 
the delivery medium is smaller than 2.4·10-3 mg/ml, that 
represent the upper limit of 30% in respect of the maximum 
solubility. This condition was verified for all tested samples in 
each withdraw. Releasing profiles obtained showed that the 
fraction of drug released from samples loaded with a smaller 
amount of PTX was greater than the fraction eluted from 
microparticles loaded with 20% in PTX. It could be 
reasonably attributed to greater interactions established 
between drug molecules in the samples loaded with a greater 
amount of active principle in respect to the samples loaded 
with a smaller amount of drug, where drug molecules are more 
dispersed in the polymeric matrix. In addition, a contained 
burst effect was detected in the first days (< 1% for C27 
microspheres loaded with 20% in PTX and < 1.5% for 5%) 
and a linear trend after the first week of test. This behaviour is 
desirable in the case of the release of drugs that could show 
toxic effects, such as Paclitaxel [48]. 
Kinetic parameters of releasing profiles were evaluated 
using equations (1) and (2) and obtained results are 
summarised in Table III. For the Peppas model, kinetic 





Fig. 5 Profiles of the PTX released from C27 microspheres loaded 
with both 5% (■) and 20% () PTX 
 
Fig. 6 Comparison between experimental and theoretical data 
obtained through the Peppas (a) and the Hopfenberg (b) models 
for the PTX released from C27 microspheres loaded with both 5% 
() and 20% () PTX 
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constant decreased with the increase in PTX and it could be 
attributed to the slower kinetic release of the drug in the 
presence of a greater amount of active principle, according as 
previously stated. Concerning drug release orders, most values 
are comprised in the range from 0.43 to 0.85, indicating an 
anomalous non-Fickian transport mechanism for swellable 
spheres. This transport mechanism is typical of polymeric 
systems not showing a solute transport controlled by the 
concentration gradient nor the macromolecular relaxation rate 
but the superposition of both diffusion and relaxation 
phenomena influence the delivery kinetics. Conversely, the 
microspheres made with PUH and PUL, have a kinetic order n 
≤ 0.43, indicating a Fickian transport mechanism typical of  
spheres made with scarcely hydrophilic or rather hydrophobic 
materials. Concerning the Hopfenberg model, kinetic 
constants k0 increase with the increase of the starting drug 
loading for all the microspheres. 
The comparison between the experimental releasing profiles 
of C27 and theoretical trends, evaluated using the kinetic 
parameters obtained through the theoretical models in the 
equations (1) and (2), are shown in Fig 6. From the correlation 
values reported in Table III, the theoretical models evaluated 
can be considered accurate and the Peppas equation can be 
used to describe the release behaviour of these systems. Also 
the release from the less hydrophilic materials fit the Peppas 
model, as can be seen from Fig. 7. On the contrary, 
Hopfenberg model is less accurate for the description of 
releasing profiles. It could be justified considering that 
Hopfenberg model was developed for surface-eroding 
polymer matrices while copolymer CL27 could be supposed to 
undergo a bulk hydration, considering that its macromolecules 
contain a fraction (~0.34) of POE that is highly hydrophilic, 
and then tend to absorb water within the whole structure of the 
microparticle. However, a further investigation of the 
degradation mechanism is necessary to validate this 
hypothesis. The particulate structure of the tested samples 
seems to overcome one of the major limits related to the 
release of drugs from biodegradable matrices, represented by a 
delivery kinetics showing a discontinuous trend. This 
characteristic was highlighted, for poly(L-lactide)-block- 
poly(oxyethylene)-block-poly(L-lactide) copolymers, in a 
paper reporting the analysis of tetracycline release from 
sintered tablets [49]. In the case of the PTX release from PCL-
POE-PCL microparticles, two distinct release mechanisms 
were not shown, likely since the degradation of the C27 is still 
very scarce after 35 days of dipping [13], and then only the 
PTX extraction by absorbed water occurs; this behaviour 
offers the advantage of more controlled delivery kinetics. 
 
IV. CONCLUSION 
In the present work a preliminary morphological, 
chemicophysical and functional characterization of a micro-
particulate delivery platform, obtained using PCL-POE-PCL 
copolymer and polyurethanes containing either copolymers 
with the same composition and different molecular weights or 
PCLdiol as soft segments, was reported. 
Morphological analysis, carried out by SEM, showed that 
the obtained particles are spherical and not aggregated, with a 
radius distributions depending on the structure of the 
macromolecular material. DSC showed that the presence of 
PTX affects the thermal properties of the macromolecules. 
Drug delivery tests showed that the starting drug payload, 
contained within the sample, affects the release kinetics; in 
particular, a faster release was detected in the samples loaded 
with the smaller amount of PTX. However, both systems 
showed the tendency to release the drug slowly, and it may 
portend that the delivery of the overall amount of PTX occurs 
with a vey sustained kinetics. It is a desirable characteristic of 
anti-mitotic delivery systems, because it provides a very 
prolonged treatment, so that it is not necessary to administer 
the drug subjecting the patient to several administrations. 
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